HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates BMRN, CACC, GOCO Investors on Securities Class Actions and Upcoming Deadlines, Encourages Investors with Losses to Contact the Firm

By GlobeNewswire

SAN FRANCISCO, Nov. 02, 2020 (GLOBE NEWSWIRE) — Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided. BMRN Investors Click Here. CACC Investors Click Here. GOCO Investors Click Here.BioMarin Pharmaceutical (BMRN) Securities Class Action:Class Period: Feb. 28, 2020 – Aug. 18, 2020 Lead Plaintiff Deadline: Nov. 24, 2020 Visit: www.hbsslaw.com/investor-fraud/BMRN Contact An Attorney Now: BMRN@hbsslaw.com          844-916-0895The complaint alleges that Defendants’ statements misrepresented and concealed material information about BioMarin’s valoctocogene roxaparvovec product candidate, potentially the first gene therapy approved by the U.S. FDA for hemophilia in the U.S.Specifically, throughout the Class Period, Defendants misstated or omitted to disclose that (1) differences between the phase 1/2 and phase 3 study of valoctocogene roxaparvovec limited the reliability of the phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect, and (2) as a result, it was foreseeable that the FDA would not approve BioMarin’s Biologics License Application (“BLA”) for valoctocogene roxaparvovec without additional data.Investors allegedly began to learn the truth on Aug. 19, 2020, when BioMarin announced it received the FDA’s complete response letter (“CRL”) to the BLA indicating the FDA recommended the company submit additional data upon completion of the phase 3 study since the difference between the phase 1/2 and phase 3 studies limited the FDA’s ability to rely on the phase 1/2 study to support the durability of effect.Analysts at Guggenheim were shocked by the Company’s disclosure, noting “[t]his news came as a negative surprise to us in light of mgt commentary and other launch-related prep (by BMRN and other payers) and pushes out a potential Roctavian approval until ~2022.”This news drove the price of BioMarin shares down over 35% that day.“We’re focused on investors’ losses and proving Defendants misled investors about the phase 1/2 reliability for the BLA,” said Reed Kathrein, the Hagens Berman partner leading the investigation.If you are a BioMarin investor or may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman.Credit Acceptance Corp. (CACC) Securities Fraud Class Action:Class Period: Nov. 1, 2019 – Aug. 28, 2020 Lead Plaintiff Deadline: Dec. 1, 2020 Visit: www.hbsslaw.com/investor-fraud/CACC Contact An Attorney Now: CACC@hbsslaw.com          844-916-0895The Complaint alleges that, throughout the Class Period, Defendants …read more

Via:: Sports Headlines


Get 20% off hat purchases for ONLY $5! Join our LIDS Club @ lids.com.
%d bloggers like this: